Immunovant, Inc. - Common Stock — キャッシュフロー (NASDAQ:IMVT) | MetaTrader

チャート全体を表示 Full chart

Financials

概要明細書統計

営業活動によるキャッシュフロー -83.33 M-106.11 M-188.19 M-214.23 M-375.87 M-407.31 M -407.31 M 投資活動によるキャッシュフロー -210 K-254 K-197 K-360 K-759 K-8 000 -8 000 財務活動によるキャッシュフロー 383.11 M200.13 M70.89 M472.43 M454.49 M595.76 M 595.76 M フリーキャッシュフロー -83.33 M-106.11 M-188.19 M-214.23 M-375.87 M-407.32 M -407.32 M

ニュース

Immunovant: Upgraded To 'Buy' Because Of IMVT-1402's Broad Potential (NASDAQ:IMVT)

Roivant: Immunovant's Rheumatoid Arthritis Win Validates The Buy (NASDAQ:ROIV)

These Analysts Increase Their Forecasts On Immunovant After Q4 Results - Immunovant (NASDAQ:IMVT)

IMVT's Q4 Loss Wider Than Expected, Stock Up 35% on Strong Study Data

原油価格が5％下落、ロウズは好決算を発表

These Two Biotech Stocks Rocketed — And One Just Broke Out

Amgen's Thyroid Eye Disease Data Rocks Rival Viridian, Makes It The Better Buy (AMGN)

Immunovant, Inc. (IMVT) Discusses Brepocitinib Program Expansion and Batoclimab Phase III Data Update Transcript

Immunovant, Inc. (IMVT) Discusses Brepocitinib Program Expansion and Batoclimab Phase III Data Update - Slideshow (NASDAQ:IMVT) 2026-04-02

Tracking Baker Brothers Portfolio – Q4 2025 Update (NASDAQ:INCY)

Immunovant Stock Surges 17% in 3 Months: What's Driving It?

Stifel reiterates Buy rating on OmniAb stock, cites partner growth